Methemoglobinemia and hemolytic anemia after rasburicase administration in a child with leukemia

Case We report a case of simultaneous methemoglobinemia and hemolytic anemia, probably related to the use of rasburicase, in a child starting treatment for acute lymphoblastic leukemia (ALL). In addition, the patient developed symptoms of pancreatitis. All complications resolved after 3 days of supp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of clinical pharmacy 2011-02, Vol.33 (1), p.58-60
Hauptverfasser:	Bauters, T., Mondelaers, V., Robays, H., De Wilde, H., Benoit, Y., De Moerloose, B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anemia Anemia, Hemolytic - chemically induced Case Report Child Humans Internal Medicine Leukemia Male Medicine Medicine & Public Health Methemoglobinemia - chemically induced Oncology Pancreatitis - complications Pancreatitis - therapy Pharmacology Pharmacy Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Side effects Tumor Lysis Syndrome - prevention & control Tumors Urate Oxidase - adverse effects Urate Oxidase - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Case We report a case of simultaneous methemoglobinemia and hemolytic anemia, probably related to the use of rasburicase, in a child starting treatment for acute lymphoblastic leukemia (ALL). In addition, the patient developed symptoms of pancreatitis. All complications resolved after 3 days of supportive therapy. Conclusion Although usually well tolerated in pediatrics, physicians prescribing rasburicase should be aware of these possible life-threatening adverse reactions.
ISSN:	2210-7703 2210-7711
DOI:	10.1007/s11096-011-9484-3